+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter, randomized, open-label study of the safety and efficacy of interferon alfa-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons



Multicenter, randomized, open-label study of the safety and efficacy of interferon alfa-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons



Hepatology 32(4 Pt 2): 558A




(PDF emailed within 1 workday: $29.90)

Accession: 035349993

Download citation: RISBibTeXText


Related references

A multi-center, randomized, open-label study of the safety and efficacy of interferon alpha-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons. Hepatology 34(4 Pt 2): 594A, 2001

Daily versus three times weekly interferon alpha-2b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons A multicenter, randomized, open-label study. Hepatology 36(4 Part 2): 582A, 2002

Open-label study of the safety and efficacy of interferon alfa-2b plus ribavirin for the treatment of HCV infection in HIV patients. Hepatology 34(4 Pt 2): 588A, 2001

A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastro-Enterologica Belgica 73(2): 223-228, 2010

An open-label, multicenter study of the efficacy and safety of peginterferon alfa-2a , alone, or in combination with ribavirin , in patients with HIV/HCV co-infection. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 310, 2003

An open-label, multicenter study of the efficacy and safety of peginterferon alfa-2A , alone or in combination with ribavirin. Journal of Hepatology 40(Suppl 1): 146, 2004

An open-label, multicenter study of efficacy and safety of peginterferon alfa-2a/ribavirin in HIV/HCV coinfection. Journal of Hepatology 38(Supplement 2): 160, 2003

Pegylated interferon alfa-2b plus ribavirin versus PEG-IFN for treatment of HIV/HCV co-infected patients An open, multicenter, randomized trial. Gastroenterology 122(4 Suppl 1): A 630, 2002

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Clinical Gastroenterology and Hepatology 8(1): 66-71.E1, 2010

Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a alone versus Peginterferon alfa-2a plus ribavirin in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a plus ribavirin An open, multicenter, randomized Trial. Hepatology 38(4 Suppl 1): 244A-245A, 2003

Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 33(1): 25-29, 2005

Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. Journal of Acquired Immune Deficiency Syndromes 35(5): 464-472, 2004

Pegylated interferon alfa-2a in combination with ribavirin Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 120(5 Supplement 1): A 55, 2001

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Hepatology International 11(2): 188-198, 2017

Safety and efficacy of interferon-alfa and interferon-alfa plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients under HAART. Hepatology 32(4 Pt 2): 555A, 2000